For a US rare disease, ATMP or cell & gene therapy biotech, Europe can look like a problem for after the US launch. It isn’t. Several of the decisions that set what Europe will be worth are made before the US launch, inside the Phase 3 design, the evidence package and the US pricing strategy. Three of them can still be shaped today.
1. Evidence requirements
EMA and European HTA bodies will ask questions a US filing does not. Comparator choice, endpoints, subgroup data and the economic evidence that payers expect are far cheaper to build into the Phase 3 package than to retrofit afterwards. Knowing what Europe will ask, before the protocol locks, protects the value of the whole programme.
2. European access strategy
Europe is not one market. Which routes (centralised approval, orphan designation, early-access and named-patient programmes), which countries, and in which sequence, these determine how quickly paid access opens and how much it is worth. The right sequence can fund later steps; the wrong one strands the asset in reimbursement limbo.
3. Pricing implications, how Europe feeds back into US net
This is the one US boards most often miss. European prices do not stay in Europe. Through international reference pricing (IRP), other markets, and increasingly US policy debate around most-favored-nation (MFN) pricing, look to the prices you set in Europe. A European launch price agreed without that line of sight can quietly compress your US net. Sequencing countries by reference-pricing exposure, and protecting the price corridor, is a pricing decision with US consequences.
The practical point
None of this requires building a European organisation before the investment case is established. It requires getting the three decisions above in front of the right senior operators early, and keeping the commitment scoped to each gate. That is exactly what a short European opportunity scan is for.
This article is general information, not regulatory, legal or financial advice.